Dolor neuropático

Joao Batista Santos-García; José Alberto Mimenza Alvarado

doi:10.47924/neurotarget2015229

Authors

Joao Batista Santos-García Medical specialist in Anesthesiology, Pain and Palliative Care. Responsible for the Pain and Palliative Care Service of the UFMA University Hospital and the Maranhão Cancer Hospital. Editor in chief of the Revista de Pain Pesquisa, Clínica y Terapéutica.
José Alberto Mimenza Alvarado Medical specialist in Neurology, Neurophysiology and Internal Medicine. Postgraduate in Cerebral Vascular Disease. National Institute of Medical Sciences and Nutrition “Salvador Zubirán”, Mexico Federal District, Mexico. Professor of the High Specialty course in Geriatric Neurology, National Autonomous University of Mexico.

DOI:

https://doi.org/10.47924/neurotarget2015229

Keywords:

neuropathy, neuropathic pain, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropath, diagnostic, treatment, evidence, recommendation

Abstract

According to the International Association for the Study of Pain (IASP) pain neuropathic is pain caused by injury or disease of the somatosensory system. Some of the diseases related are post-herpetic neuralgia, trigeminal neuralgia and diabetic neuropathy. These neurological disorders are characterized by chronic pain with dysesthesia, which significantly affects physical and emotional disturbances in the patient. The treatment is based on antidepressants, antiepileptics and local anesthetics.

Metrics

Metrics Loading ...

References

Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systemic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73

Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-5.

Daniel HC, Narewska J, Serpell M, Hoggart B, Johnson R, Rice AS. Com- parison of psychological and physical function in neuropathic pain and nociceptive pain: implications forcognitive behavioral pain management programs. Eur J Pain. 2008;12(6):731-41.

Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526-33.

Watson CP, Deck JH, Morshead C, Van der Kooy D, Evans RJ. Post- herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain. 1991;44(2):105-17.

Bennett GJ. Hypotheses on the pathogenesis of herpes zoster-associated pain. Ann Neurol. 1994;35 Suppl:S38-41.

Obermann M, Katsarava Z. Update on trigeminal neuralgia. Expert Rev Neurother. 2009;9(3):323-9.

Said G, Lacroix C, Lozeron P, Ropert A, Planté V, Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain. 2003;126(Pt 2):376- 85.

Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3-14.

McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712-20.

Sullivan MD, Robinson JP. Antidepressant and anticonvulsant medication for chronic pain. Phys Med Rehabil Clin N Am. 2006;17(2):381-400, vi-vii.

O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009 Oct;122(10 Suppl):S22-32.

Attal N, Finnerup NB. Pharmacological management o neuropatic pain. Clin Updates 2010;18(9):1-8.

Kalso E. Pharmacological management of pain: anticonvulsants, antidepressants, and adjuvants analgesics. In: International Association for the Study of Pain (IASP). Pain an updated review: refresher course syllabus. Seatle, Washington: IASP Press; 2005. p. 19-29.

Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):e164.

Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015 Jul 6;7:CDoo8242.

Estebe JP, Myers RR. Amitriptyline neurotoxicity: dose-related pathology after topical application to rat sciatic nerve.Anesthesiology. 2004;100(6):1519-25.

Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence=based algrithm for the treatment os neuropathic pain. MedGenMed. 2007;9(2):36.

King JB, Schauerhamer MB, Bellows BK. A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain. Ther Clin Risk Manag. 2015;11:1163-75.

Bohlega S, Alsaadi T, Amir A, Hosny H, Karawagh AM, Moulin D, et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the middle East region. J Int Med Res. 2010;38(2):295-317.

Tasmuth T, Härtel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002;6(1):17-24.

Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015 Aug 23;8:CD011091.

Haanpää ML, Gourlay GK, Kent JL, Miaskowski C, Raja SN, Schmader KE, Wells CD. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc. 2010;85(3 Suppl):S15-25.

Zhang J, Ho KY, Wang Y. Efficacy of pregabalin in acute postoperative pain: a meta-analysis. Br J Anaesth. 2011 Apr;106(4):454-62.

Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm. 2007;64(14):1475-82.

Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD007938.

Pregabalin (lyrica) for neuropathic pain and epilepsy. Med Lett Drugs Ther. 2005;47(1217):75-6, 73.

Mimenza-Alvarado A, Aguilar-Navarro S. Comparative clinical trial of safety and tolerability of Gabapentin plus Vitamin b1/b12 versus Pregabalin in the treatment of painful peripheral diabetic neuropathy. J Pain Relief. 2014;S3:1-6.

Medina-Santillán R, Morales-Franco G, Espinoza-Raya J, Granados-Soto V, Reyes-García G. Treatment of diabetic neuropathic pain with gabapentin alone or combined with vitamin B complex. Preliminaryresults. Proc West Pharmacol Soc. 2004;47:109-12.

Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology. 2008;71(15):1183-90.

Oomens MA, Forouzanfar T. Pharmaceutical management of trigeminal neuralgia in the elderly. Drugs Aging. 2015;32(9):717-26.

Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, et al; American Academy of Neurology Society; European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013-28.

Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: topical lidocaine is effective in nociceptor deprived skin. J Neurol. 2005;252(6):677-86.

Marmura MJ. Intravenous lidocaine and mexiletine in the management of trigeminal autonomic cephalalgias. Curr Pain Headache Rep. 2010;14(2):145-50.

Hollingshead J, Dühmke RM, Cornblath DD, Hollingshead JR.DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev. 2006;(3):CD003726.

Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chro- nic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589-94.

Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9(1):1-39.

McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD006146.

Sommer C, Welsch P, Klose P, Schaefert R, Petzke F, Häuser W. [Opioids in chronic neuropathic pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration]. [Article in German] Schmerz. 2015;29(1):35-46.

Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59(7):1015-21.

Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;6:CD010692.

Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD005451.

Baron R, Naleschinski D, Hullemann P, Mahn F. Complex regional pain syndrome: a neuropathic disorder? In: Mogil JS, editor.Pain. An updated review: refresher course syllabus. Seatle, Washington: IASP Press; 2010; 109-17.

Birklein F, O'Neill D, Schlereth T. Complex regional pain syndrome: An optimistic perspective. Neurology. 2015;84(1):89-96.

Grieve S, Jones L, Walsh N, McCabe C. What outcome measures are commonly used for Complex Regional Pain Syndrome clinical trials? A systematic review of the literature. Eur J Pain. 2015. doi: 10.1002/ ejp.733. [Epub ahead of print]

Bussa M, Guttilla D, Lucia M, Mascaro A, Rinaldi S. Complex regional pain syndrome type I: a comprehensive review. Acta Anaesthesiol Scand. 2015;59(6):685-97.

Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48(5):1212-8.

Zin CS, Nissen LM, Smith MT, O'Callaghan JP, Moore BJ. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417-42.

Zhou HY, Chen SR, Pan HL. Targeting N-methyl-D-aspartate recep- tors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011;4(3):379-88.

Connolly SB, Prager JP, Harden RN. A systematic review of ketamine for complex regional pain syndrome. Pain Med. 2015;16(5):943-69.

Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain. 2010;14(4):387-94.

Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med. 2008;9(2):253-7.

Peppin JF, Pappagallo M. Capsaicinoids in the treatment of neuropathic pain: a review. Ther Adv Neurol Disord. 2014;7(1):22-32.

Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013;2:CD007393.

European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report for Qutenza: capsaicin [Internet]. Londres, UK: EMEA/CHMP; 2009 [citado 11 may 2015]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000909/WC500040450.pdf.

Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2012;9:CD010111.

Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences (Riyadh). 2015;20(2):107-14.

Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology. 2008;71(15):1183-90.

Zakrzewska JM, Linskey ME. Trigeminal neuralgia. BMJ. 2015;350:h1238.

Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol. 1984;15(3):240-4.

Leandri M, Lundardi G, Inglese M, Messmer-Uccelli M, Mancardi GL, Gottlieb A, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol. 2000;247(7):556-8.

Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev. 2011;(2):CD006044.

Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;12:CD006044.

Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 2. Am J Health Syst Pharm. 2006;63(3):225-32.

Sycha T, Kranz G, Auff E, Schnider P. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature. J Neurol. 2004;251 Suppl 1:I19-30.

Orsini M, Leite MA, Chung TM, Bocca W, de Souza JA, de Souza OG, et al. Botulinum Neurotoxin Type A in Neurology: Update. Neurol Int. 2015;7(2):5886.

Mendlik MT, Uritsky TJ. Treatment of Neuropathic Pain. Curr Treat Op- tions Neurol. 2015;17(12):50.

Oh HM, Chung ME. Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins (Basel). 2015;7(8):3127-54.

Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep. 2010;2:52.

Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6(1):15-28.

Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil. 2005;84(9):649-54.

Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1-3):210-20.

Lynch ME, Campbekk F. Cannabinoids for systemic review of randomized trials. Br J Clin Pharmacol 2011;72(5):735-44.

Jensen B, Chen J, Furnish T, Wallace M. Medical marijuana and chronic pain: a review of basic science and clinical evidence. Curr Pain Headache Rep. 2015;19(10):50.

Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713-37.

O’Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137(1):96-111.

Markman JD, Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. J Pain. 2006;7(1 Suppl 1):S38-47.

Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223-32.

Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-19.

Walco GA, Dworkin RH, Krane EJ, LeBel AA, Treede RD. Neuropathic pain in children: Special considerations. Mayo Clin Proc. 2010;85(3 Suppl):S33-41.

Boychuk DG, Goddard G, Mauro G, Orellana MF. The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain. J Pain. 2006;7: a systematic review. J Oral Facial Pain Headache. 2015;29(1):7-14.

Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. Can Fam Physician. 2015;61(8):e372-81.

Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al; Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-35.

Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669-78.

Debruyne D, Le Boisselier R. Emerging drugs of abuse: current perspectives on synthetic cannabinoids. Subst Abuse Rehabil. 2015;6:113-29.

Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain:

Systematic review of randomized controlled trials. Can Fam Physician. 2015;61(8):e372-81.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-73. Erratum in: JAMA. 2015;314(8):837; JAMA. 2015;314(5):520.

US Food and Drug Administration (FDA). Prialt (ziconotide intrathecal infusion [Internet]. Silver Spring, MD: FDA; 2007 [citado 2 set 2015]. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021060s003lbl.pdf

Mathur VS. Ziconotide: a new pharmacological class of drug for the management of pain. Seminars in Anaesthesia, Perioperative Medicine and Pain 2000;19(2):67-75.

US Food and Drug Administration (FDA). Appoval package for Application number 21-060 – Prialt (ziconotide intrathecal infusion) [Internet]. Silver Spring, MD: FDA; 2007 [citado 2 set 2015]. Disponible en: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21060_Prialt_Ap-prov.PDF

Rauck RL, Wallace MS, Burton AW, Kapural L, North JM. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract. 2009;9(5):327-37.

Pope JE, Deer TR. Ziconotide: a clinical update and pharmacologic review. Expert Opin Pharmacother. 2013;14(7):957-66.

Perez RS, Zollinger PE, Dijkstra PU, Thomassen-Hilgersom IL, Zuurmond WW, Rosenbrand KC, et al; CRPS I task force. Evidence based guidelines for complex regional pain syndrome type 1. BMC Neurol. 2010;10:20.

Cossins L, Okell RW, Cameron H, Simpson B, Poole HM, Goebel A. Treatment of complex regional pain syndrome in adults: a systematic review of randomized controlled trials published from June 2000 to Fe- bruary 2012. Eur J Pain. 2013;17(2):158-73.

Varenna M, Adami S, Sinigaglia L. Bisphosphonates in Complex Regional Pain syndrome type I: how do they work? Clin Exp Rheumatol. 2014;32(4):451-4.

Giusti A, Bianchi G. Treatment of complex regional pain syndrome type I with bisphosphonates. RMD Open. 2015;1(Suppl 1):S38-47e000056.

Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223-32.

Prommer E. Levorphanol: revisiting an underutilized analgesic. Palliat Care. 2014;8:7-10.

Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-19.

Walco GA, Dworkin RH, Krane EJ, LeBel AA, Treede RD. Neuropathic pain in children: Special considerations. Mayo Clin Proc. 2010;85(3 Suppl):S33-41.